ReviewPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2018
DNA and mRNA vaccination against allergies.
Review in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Messenger RNA vaccines in the prevention of allergic diseases.The World Allergy Organization journal · 2025Review
- The Junction of Allergic Inflammation and Atherosclerosis: Pathways and Clinical Implications-A Review.Life (Basel, Switzerland) · 2025Review
- Safety and efficacy of aJournal of veterinary science · 2025Article
- Article
- New insights for the development of efficient DNA vaccines.Microbial biotechnology · 2024Review
- Application of Nanoparticles for Immunotherapy of Allergic Rhinitis.International journal of nanomedicine · 2024Review
- Allergen immunotherapy: past, present and future.Nature reviews. Immunology · 2023Review
- New approaches to immunotherapy in house dust mite allergy.Clinical and experimental pediatrics · 2023Article
- Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice.Archives of virology · 2022Article
- Co-administration of a plasmid encoding CD40 or CD63 enhances the immune responses to a DNA vaccine against bovine viral diarrhea virus in mice.The Journal of veterinary medical science · 2022Article
- mRNA vaccines: the most recent clinical applications of synthetic mRNA.Archives of pharmacal research · 2022Review
- Principles in Immunology for the Design and Development of Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Review
- mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Peanut oral immunotherapy: current trends in clinical trials.Immunotherapy advances · 2022Review
- Allergen immunotherapy for food allergy: Evidence and outlook.Allergologie select · 2022Review
- B cells and food allergy.Current opinion in pediatrics · 2021Review
- Review
- AMDV Vaccine: Challenges and Perspectives.Viruses · 2021Review
- mRNA-Based Vaccines.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Allergen-specific immunotherapy, which is performed by subcutaneous injection or sublingual application of allergen extracts, represents an effective treatment against type I allergic diseases. However, due to the long duration and adverse reactions, only a minority of patients decides to undergo this treatment. Alternatively, early prophylactic intervention in young children has been proposed to stop the increase in patient numbers. Plasmid DNA and mRNA vaccines encoding allergens have been shown to induce T helper 1 as well as T regulatory responses, which modulate or counteract allergic T helper 2-biased reactions. With regard to prophylactic immunization, additional safety measurements are required. In contrast to crude extracts, genetic vaccines provide the allergen at high purity. Moreover, by targeting the encoded allergen to subcellular compartments for degradation, release of native allergen can be avoided. Due to inherent safety features, mRNA vaccines could be the candidates of choice for preventive allergy immunizations. The subtle priming of T helper 1 immunity induced by this vaccine type closely resembles responses of non-allergic individuals and-by boosting via natural allergen exposure-could suffice for long-term protection from type I allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.